TY - JOUR
T1 - Bisphenol A inhibits Cl- secretion by inhibition of basolateral K+ conductance in human airway epithelial cells
AU - Ito, Yasushi
AU - Sato, Shinji
AU - Son, Masami
AU - Kondo, Masashi
AU - Kume, Hiroaki
AU - Takagi, Kenzo
AU - Yamaki, Kenichi
PY - 2002
Y1 - 2002
N2 - There has been growing concern about the potential threat of hormone-disrupting chemicals like bisphenol A to various aspects of animal and human health. We studied the effects of bisphenol A on the Cl- secretion in human airway epithelial Calu-3 cells. Pretreatment with bisphenol A (IC50 = 60 μM, for 30 min) prevented isoproterenol (10 nM)-generated short-circuit current (Isc) more potently than 17 β-estradiol or tamoxifen (IC50 = 1 mM). 5′-Nitro-2-(3-phenylpropylamino) benzoate-sensitive apical conductance potentiated by isoproterenol was not affected by the pretreatment with either of these estrogenic compounds. The effects of bisphenol A were simulated in Isc responses to forskolin (10 μM) and 8-bromo-cAMP (1 mM). Nystatin permeabilization of Calu-3 monolayers revealed that bisphenol A attenuated 8-bromo-cAMP-induced basolateral K+ current, which is sensitive to clotrimazole (30 μM) and insensitive to charybdotoxin (100 nM), without affecting the apical CI- current. Bisphenol A, but neither 17 β-estradiol nor tamoxifen, interrupted the charybdotoxin-sensitive component of /sc stimulated by 1-ethyl-2-benzimidazolinone (1-EBIO; 500 μM). The inhibitory effects of bisphenol A on these Cl- secretory stimuli were remarkable when applied to the apical rather than the basolateral membrane. Alternatively, long-term incubation of bisphenol A (1 μM; 12-72 h) had no discernible effect on isoproterenol- and 1-EBIO-induced Cl- secretion. These findings indicate that short-term exposure to bisphenol A attenuates transepithelial CI- secretion through inhibition of both cAMP- and Ca2+-activated K+ channels on the basolateral membrane, interacting from the cytosolic surface in Calu-3 cells.
AB - There has been growing concern about the potential threat of hormone-disrupting chemicals like bisphenol A to various aspects of animal and human health. We studied the effects of bisphenol A on the Cl- secretion in human airway epithelial Calu-3 cells. Pretreatment with bisphenol A (IC50 = 60 μM, for 30 min) prevented isoproterenol (10 nM)-generated short-circuit current (Isc) more potently than 17 β-estradiol or tamoxifen (IC50 = 1 mM). 5′-Nitro-2-(3-phenylpropylamino) benzoate-sensitive apical conductance potentiated by isoproterenol was not affected by the pretreatment with either of these estrogenic compounds. The effects of bisphenol A were simulated in Isc responses to forskolin (10 μM) and 8-bromo-cAMP (1 mM). Nystatin permeabilization of Calu-3 monolayers revealed that bisphenol A attenuated 8-bromo-cAMP-induced basolateral K+ current, which is sensitive to clotrimazole (30 μM) and insensitive to charybdotoxin (100 nM), without affecting the apical CI- current. Bisphenol A, but neither 17 β-estradiol nor tamoxifen, interrupted the charybdotoxin-sensitive component of /sc stimulated by 1-ethyl-2-benzimidazolinone (1-EBIO; 500 μM). The inhibitory effects of bisphenol A on these Cl- secretory stimuli were remarkable when applied to the apical rather than the basolateral membrane. Alternatively, long-term incubation of bisphenol A (1 μM; 12-72 h) had no discernible effect on isoproterenol- and 1-EBIO-induced Cl- secretion. These findings indicate that short-term exposure to bisphenol A attenuates transepithelial CI- secretion through inhibition of both cAMP- and Ca2+-activated K+ channels on the basolateral membrane, interacting from the cytosolic surface in Calu-3 cells.
UR - http://www.scopus.com/inward/record.url?scp=0036084907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036084907&partnerID=8YFLogxK
U2 - 10.1124/jpet.302.1.80
DO - 10.1124/jpet.302.1.80
M3 - Article
C2 - 12065703
AN - SCOPUS:0036084907
SN - 0022-3565
VL - 302
SP - 80
EP - 87
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -